Sydney, Australia – 12 November 2024 | LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce its new strategic joint venture with the Restorative Sexual Health Clinic Pty Ltd (RSHC), a prominent Australian men’s health group, to launch an online healthcare platform dedicated to men’s health. The platform will provide accessible, comprehensive health services, including medical consultations, therapeutic services, prescription treatments, and integrated health management solutions.
Highlights:
-
Strategic Partnership/Joint Venture: The joint venture combines LTR Pharma’s pharmaceutical expertise with RSHC’s clinical experience in the men’s health space to create a digital platform offering discreet and convenient healthcare access online.
-
Service Offering: The online platform will provide men with:
-
Professional medical consultations
-
Comprehensive therapeutic services
-
Prescription and non-prescription treatments
-
Integrated health management solutions
-
-
Launching 2024: The platform is set to launch in Q1 2025, positioning LTR Pharma to capitalise on the rapid growth of the global telehealth market, valued at over USD $140 billion in 2023, with a projected growth rate of 22% annually through to 2032.
Lee Rodne, Chairman of LTR Pharma, commented: "This joint venture represents a significant milestone in LTR Pharma's strategic commercialisation plan. By partnering with an established leader in men's health services, we are well-positioned to meet the growing demand for accessible healthcare solutions. The online platform will provide a discrete and convenient channel for men to access professional healthcare services and prescribed treatments."
Melissa Hadley Barrett, Founder of the Restorative Sexual Health Clinic, added: "This partnership aligns perfectly with our mission to provide comprehensive, evidence-based care that enhances men's well-being. The online platform will expand access to our professional services while maintaining the high standards of care that define our face-to-face clinic. We look forward to working with LTR Pharma to deliver innovative healthcare solutions that make a meaningful difference in men's lives."
Market Opportunity:
The venture leverages the growing acceptance of digital health solutions around the globe and in Australia, particularly when it comes to sensitive health issues and issues in the men’s health space. The online platform aligns with increasing smartphone adoption and improved internet speeds and accessibility, creating new opportunities in the telehealth space for men’s health consultations and prescriptions.
Media Enquiries
Haley Chartres
haley@hck.digital
Investor Enquiries
Peter McLennan
investors@ltrpharma.com
About us:
About LTR Pharma Ltd:
LTR Pharma is focused on improving men’s health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma’s lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.
Contact details:
Jane Morgan
Jane Morgan Management
Investor & Media Relations
jm@janemorganmanagement.com.au
